PURPOSE: To enable to apply an improved antibody to the clinical treatments of cancers, etc., by subjecting an antigen-determining group on a human α/β T-cell receptor(TCR) recognized with a monoclonal antibody BMA 031 to an immune reaction.
CONSTITUTION: This improved antibody against the human α/β T cell receptor is obtained by immunizing a mouse with a human peripheral blood T-lymphocyte separated from a mouse by E-Rosette method, culturing (A) the obtained hybridoma cell BMA 031, and subsequently cloning the obtained culture product, thus obtaining (B) the monoclonal antibody (mAbs) having properties such as (a) IgG 2b isotype, (b) specificities on the α and β chains of a TCR/CD3 receptor complex, (c) a heavy chain amino acid sequence comprising a variable region of formula I, (d) a light chain amino acid sequence comprising a variable region of formula II, and (e) a sequence in which the sequence (d) is less than sequences in all constant regions. If necessary, the component B is compounded with a pharmaceutically acceptable carrier to produce a pharmaceutical composition.
GOODON PII MUUA
ROORANTO KURURE
FURITSUTSU ZAIRAA
BEHRINGWERKE AG
Next Patent: METHOD FOR SELECTIVELY ESTERIFYING ENANTIOMER OF RACEMIC CARBOXYLIC ACID